Hyundai Motor Co. has doubled its issuance of corporate bonds to 600 billion won due to strong demand.
The debt has a maturity period of three to seven years.
The company made the sale to refinance maturing dollar-denominated debt.
According to a Hyundai spokesperson, the company initially planned to issue 300 billion won in corporate bonds but changed its mind due to strong demand.
Hyundai was struck by regulations to stem the spread of COVID-19, forcing it to suspend operations in most of its 10 overseas plants, including four in China.
The company's plant in Alabama has restarted production while those in China are operating, although not yet in full capacity.
Hyundai's overseas plants, along with its seven domestic plants, have a combined capacity to produce 5.5 million vehicles.
Hyundai's net profit in the first quarter plummeted 42 percent to 552.68 billion won from 953.79 billion won from a year before due to the outbreak, which disrupted its production and sales.


TSMC Exits Arm Holdings with $231 Million Share Sale Amid Strategic Portfolio Shift
Standard Chartered Q1 Profit Hits Record on Wealth and Investment Banking Growth
T-Mobile Beats Q1 Earnings Expectations on Strong Postpaid Growth
Apple Q2 2026 Earnings Surge as iPhone 17 Sales Drive Record Revenue
Samsung Reports Record Profit as AI Boom Drives Memory Chip Demand
Seagate Stock Surges After Strong Q3 Earnings Beat and Bullish Outlook
NAB First-Half Earnings Miss Forecasts Amid Rising Global Risks
GameStop Eyes eBay Acquisition as Stock Prices Surge After Hours
Amazon Stock Dips Despite Record Earnings as AI Infrastructure Spending Surges
Qualcomm Stock Surges Despite Weak Guidance After Q2 2026 Earnings Beat
GameStop Proposes $56 Billion eBay Acquisition in Bold Strategic Move
Meta Raises 2026 Capex Outlook Amid AI Spending Surge, Shares Drop After Earnings
Robinhood Q1 Earnings Miss Expectations, Stock Drops After Hours
Alphabet Earnings Surge on AI Growth, Cloud Revenue, and Strong Search Performance
Berkshire Hathaway Meeting Sees Shift as Greg Abel Steps Into Leadership Spotlight
AstraZeneca Q1 2026 Earnings Surge on Strong Oncology and Rare Disease Drug Sales
Microsoft Azure Growth Forecast Beats Expectations Amid Rising AI Competition 



